Studies within Studies

Excerpt

To the Editors: Drs. Toto and colleagues (1) recently described eight patients who had reversible renal insufficiency that was attributed to the use of an angiotensin-converting enzyme inhibitor. They noted that these eight patients were identified during a randomized trial, which was annotated as their reference 9 (2). They further noted that three of the eight cases had been partially reported in their reference 10 (3).

They described the randomized trial: seventy-three patients were treated with various antihypertensive agents and were randomized to receive an angiotensin-converting inhibitor or a placebo. Reference 9, however, appears to report a different randomized trial.